Business
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
OSAKA, Japan, May 13, 2026--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth.
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":320,"url":"https://media.zenfs.com/en/business-wire.com/1f28b6b24d04a1b85b1bbca28ae66141"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Zu2cqNZeWjxDo4My4apIgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1f28b6b24d04a1b85b1bbca28ae66141","width":480,"height":320},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/gIG_DiV0bRx4A0V5gCPoHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQyNztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1f28b6b24d04a1b85b1bbca28ae66141","width":480,"height":320}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches","length":68,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Achieved Latest FY2025 Management Guidance","length":42,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Takeda is Entering a New Era & Transforming for Growth Acceleration","length":71,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":181,"olType":false},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"OSAKA, Japan, May 13, 2026--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth.","length":357,"tagName":"p"},{"type":"text","content":"Key Highlights for FY2025","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch Products. On a Core basis, Revenue decreased by 2.6% at Constant Exchange Rate (CER).","length":250,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Core Operating Profit increased by 0.8% YoY at AER and declined by 0.9% at CER, protected by OPEX savings, while still investing for growth.","length":140,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","cont...